As of 2026-03-21, the Relative Valuation of Bristol-Myers Squibb Co (BMY) is 71.83 USD. This relative valuation is based on P/E multiples. With the latest stock price at 57.48 USD, the upside of Bristol-Myers Squibb Co based on Relative Valuation is 25.0%.
The range of the Relative Valuation is 61.04 - 85.33 USD.
| Range | Selected | |
| Trailing P/E multiples | 17.6x - 23.8x | 19.0x |
| Forward P/E multiples | 16.1x - 20.5x | 18.7x |
| Fair Price | 61.04 - 85.33 | 71.83 |
| Upside | 6.2% - 48.4% | 25.0% |
| Date | P/E |
| 2026-03-20 | 16.59 |
| 2026-03-19 | 16.77 |
| 2026-03-18 | 17.14 |
| 2026-03-17 | 17.24 |
| 2026-03-16 | 17.24 |
| 2026-03-13 | 17.05 |
| 2026-03-12 | 17.02 |
| 2026-03-11 | 17.31 |
| 2026-03-10 | 17.36 |
| 2026-03-09 | 17.50 |
| 2026-03-06 | 17.40 |
| 2026-03-05 | 17.53 |
| 2026-03-04 | 17.99 |
| 2026-03-03 | 17.67 |
| 2026-03-02 | 17.99 |
| 2026-02-27 | 18.00 |
| 2026-02-26 | 17.64 |
| 2026-02-25 | 17.69 |
| 2026-02-24 | 17.78 |
| 2026-02-23 | 17.68 |
| 2026-02-20 | 17.51 |
| 2026-02-19 | 17.41 |
| 2026-02-18 | 17.24 |
| 2026-02-17 | 17.42 |
| 2026-02-13 | 17.53 |
| 2026-02-12 | 17.28 |
| 2026-02-11 | 17.30 |
| 2026-02-10 | 17.57 |
| 2026-02-09 | 17.54 |
| 2026-02-06 | 17.89 |
| 2026-02-05 | 17.18 |
| 2026-02-04 | 16.63 |
| 2026-02-03 | 16.16 |
| 2026-02-02 | 16.13 |
| 2026-01-30 | 15.89 |
| 2026-01-29 | 15.67 |
| 2026-01-28 | 15.77 |
| 2026-01-27 | 16.04 |
| 2026-01-26 | 15.76 |
| 2026-01-23 | 15.78 |
| 2026-01-22 | 15.86 |
| 2026-01-21 | 15.73 |
| 2026-01-20 | 15.65 |
| 2026-01-16 | 15.95 |
| 2026-01-15 | 16.34 |
| 2026-01-14 | 16.46 |
| 2026-01-13 | 16.14 |
| 2026-01-12 | 16.10 |
| 2026-01-09 | 16.12 |
| 2026-01-08 | 16.14 |